Safe S.A. specializes in the design, manufacture and marketing of medical devices for spine surgery. The company offers implants and instruments in the range of SteriSpine (the first spinal arthrodesis system that is for single use and is sterile and totally traceable). The group's activity is organized around 2 areas: - direct and indirect sales of medical devices (Safe Orthopaedics): business carried out in France, Germany, the United Kingdom, the United States and South America; - subcontracted manufacturing services for orthopedic medical devices (Safe Medical).

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	128K 143K 119K 108K 204K 13.77M 205K 1.44M 558K 7.03M 537K 525K 22.58M	P/E 2024 *	-	P/E 2025	-0.07x
Enterprise Value	13.24M 14.84M 12.33M 11.22M 21.14M 1.43B 21.3M 149M 57.99M 729M 55.71M 54.51M 2.34B	EV / Sales 2024	2.39x	EV / Sales 2025	2.47x
Free-Float	87.27%	Yield 2024 *	-	Yield 2025	-

06-30	Safe Group sharply improves its full-year results
06-28	Safe Orthopaedics SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-28	Safe And ABL Alpstein Sign Exclusive Distribution Agreement For SteriSpine Range In Peru	CI
05-28	Safe Group enters Peru with exclusive distribution agreement
03-16	Changes to the SAFE Board of Directors
12-17	Safe Orthopaedics Signs Exclusive Distribution Agreement for Spanish Market	MT
12-17	Safe Group Signs Strategic Distribution Agreement in Spain with Vortrom Biologics	CI
11-30	Safe Orthopaedics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/07/25	Alert wrongly tagged to Safe SA withdrawn	RE
27/12/24	Safe Orthopaedics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
09/09/24	The market burns its idols
05/02/24	Safe: wins its appeal against Neo Medical
28/12/23	Safe: audit initiated for a turnaround plan

12-22	SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY	GL
12-17	SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS	GL
12-17	SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS	AQ
09/09/24	New bond financing agreement in a minimum amount of €3 million in anticipation of validation of the continuation plan	GL
24/11/23	Safe group announces the convocation of the Annual General Meeting of Shareholders to be held on December 15th 2023 and provides an update on the situation	AQ

09-08	SAFE : point sur l'audience du 7 septembre 2026 devant le Tribunal des activités économiques de Lyon
08-25	SAFE Group : point sur la suspension de cotation et sur la certification des comptes annuels 2025
06-30	Safe Group améliore nettement ses résultats annuels
05-28	Safe Group s'implante au Pérou avec un accord de distribution exclusif
04-28	Safe S A : Report de la publication des résultats annuels 2025 de SAFE Group

Manager	Title	Age	Since
Nicolas Papillon CEO	Chief Executive Officer	46	-
Thomas Droulout CTO	Chief Tech/Sci/R&D Officer	50	14/02/2010
François-Henri Reynaud DFI	Director of Finance/CFO	-	08/11/2017

Safe Orthopaedics Share Price Euronext Paris

Stocks

Medical Equipment, Supplies & Distribution

Valuation: Safe Orthopaedics

Latest news: Safe Orthopaedics

Press Releases: Safe Orthopaedics

News in other languages: Safe Orthopaedics

Quotes and Performance

Managers and Directors: Safe Orthopaedics

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Thomas Droulout BRD	Director/Board Member	50	-
François-Henri Reynaud BRD	Director/Board Member	-	25/11/2019
Ismaël Nujurally BRD	Director/Board Member	69	25/11/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SAFE ORTHOPAEDICS	-0.79%	-8.36%	-	-	144K
ABBOTT LABORATORIES	+2.80%	-0.72%	-25.04%	+4.21%	169B
MEDTRONIC PLC	+1.85%	-1.56%	-10.49%	+15.69%	110B
STRYKER CORPORATION	+3.56%	+3.37%	-22.30%	+7.47%	106B
ESSILORLUXOTTICA	+1.19%	-1.10%	-47.66%	-11.35%	73.87B
CENCORA, INC.	+1.83%	+3.36%	+2.86%	+69.71%	58.98B
HOYA CORPORATION	+1.32%	+4.32%	+14.41%	+64.37%	51.28B
BECTON, DICKINSON AND COMPANY	+2.15%	-1.94%	-6.11%	-30.95%	48.16B
IDEXX LABORATORIES, INC.	+1.76%	-0.17%	-15.87%	+22.68%	40.84B
DEXCOM, INC.	+1.80%	+0.28%	+30.98%	+3.48%	32.21B
Average	+1.71%	-0.86%	-8.80%	+16.15%	76.69B
Weighted average by Cap.	+2.21%	-1.30%	-14.92%	+13.55%

	2024	2025
Net sales	5.04M 5.65M 4.7M 4.27M 8.05M 544M 8.11M 56.75M 22.08M 278M 21.21M 20.76M 893M	5.36M 6.01M 5M 4.55M 8.56M 579M 8.63M 60.38M 23.49M 296M 22.57M 22.08M 950M
Net income	-1.93B -2.16B -1.8B -1.64B -3.08B -208B -3.1B -21.72B -8.45B -106B -8.12B -7.94B -342B	-4.67M -5.24M -4.35M -3.96M -7.46M -505M -7.52M -52.62M -20.47M -258M -19.67M -19.24M -828M
Net Debt	11.47M 12.86M 10.69M 9.73M 18.31M 1.24B 18.45M 129M 50.24M 632M 48.27M 47.23M 2.03B	13.11M 14.7M 12.22M 11.12M 20.93M 1.42B 21.09M 148M 57.43M 722M 55.18M 53.99M 2.32B